Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

Meeting Between State Tobacco Monopoly Administration and South Nanyang Brothers

Sep.27.2024
Meeting Between State Tobacco Monopoly Administration and South Nanyang Brothers
Wang Gongcheng, deputy director of State Tobacco Monopoly Administration, met with Zhang Yaohua from Nanyang Brothers Tobacco in Beijing.

On September 27, Wang Gongcheng, member of the Party Committee and deputy director of the State Tobacco Monopoly Administration, met with Zhang Yaohua, the Director General of Nanyang Brothers Tobacco Co., Ltd., in Beijing. The two sides held friendly discussions.


Officials from the National Bureau of Administration (Department of Foreign Affairs), Development Planning Department, and the China Tobacco International Limited Company attended the meeting.


References:
[1] 王宫成会见南洋兄弟烟草股份有限公司董事总经理张耀华
Also Read:
[1] Meeting between STMA Deputy Director and ABF Illicit Tobacco and E-cigarette Commissioner Erin Dale
[2] Meeting between State Tobacco Administration and Philip Morris International CEO.
[3] Meeting between State Tobacco Monopoly Administration Vice Director and KT&G Deputy President
[4] Meeting Between State Tobacco Monopoly Administration and English-American Tobacco Group
[5] Meetings Between State Tobacco Monopoly Administration and Global Tobacco Companies
[6] Meeting between STMAD and PMI President of China Strategic Cooperation
[7] Meeting between State Tobacco Monopoly Administration and JTI Executives
[8] Meeting between STMA and British American Tobacco Group Members
#FIRSTUNION

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

INTER-TABAC
INTER-TABAC
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Russian Lawmakers Propose Criminalizing E-Cigarette Manufacture and Distribution, Citing Health Risks
Russian Lawmakers Propose Criminalizing E-Cigarette Manufacture and Distribution, Citing Health Risks
Russian lawmakers propose criminalizing e-cigarette manufacturing, storage, sales, and use, citing drug crime model for penalties.
Oct.14 by 2FIRSTS.ai
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
As the EU finalizes its Cardiovascular Health Plan, public feedback reveals a sharp divide over nicotine policy.A 2Firsts analysis of 677 submissions found that nearly one in four mentioned tobacco — highlighting tension between strict control and harm reduction approaches.
Oct.07
Thai Cabinet Approves NHRC Proposal to Tighten E-Cigarette Regulation
Thai Cabinet Approves NHRC Proposal to Tighten E-Cigarette Regulation
Thailand’s Cabinet approved a National Human Rights Commission proposal to tighten e-cigarette regulation. The Health Ministry was instructed to raise public awareness on vaping risks and amend the 2017 Tobacco Control Act to cover all tobacco products, including vapes and new forms, while enforcing WHO FCTC Article 5.3 to prevent industry interference.
Oct.28 by 2FIRSTS.ai
Jinjia Venture Faces New Judicial Auction, Control Unchanged
Jinjia Venture Faces New Judicial Auction, Control Unchanged
Jinjia Group said its controlling shareholder, Jinjia Venture, will have part of its holdings auctioned by the Shenzhen Nanshan Court, involving 43.4 million shares. Earlier, the Shenzhen Intermediate Court announced another auction of 37.27 million shares. Together they represent 5.56% of total equity. Jinjia said the auctions will not affect company control.
Oct.23 by 2FIRSTS.ai
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
According to media reports, a leaked European Commission document indicates the EU plans to push for its strictest regulatory framework on nicotine and tobacco products at COP11 in Switzerland this November, including measures such as a full ban on nicotine pouches and flavoured products.
Oct.10 by 2FIRSTS.ai
Related Topics
News
Related Read
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
2FIRSTS.ai
Russian Lawmakers Propose Criminalizing E-Cigarette Manufacture and Distribution, Citing Health Risks
Russian Lawmakers Propose Criminalizing E-Cigarette Manufacture and Distribution, Citing Health Risks
2FIRSTS.ai
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
EU Cardiovascular Health Plan Consultation Highlights Tobacco Debate — 2Firsts Analysis Reveals Divide Between “Cessation” and “Harm Reduction” Approaches
Thai Cabinet Approves NHRC Proposal to Tighten E-Cigarette Regulation
Thai Cabinet Approves NHRC Proposal to Tighten E-Cigarette Regulation
2FIRSTS.ai
Jinjia Venture Faces New Judicial Auction, Control Unchanged
Jinjia Venture Faces New Judicial Auction, Control Unchanged
2FIRSTS.ai
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
Leaked EU Paper Suggests COP11 Push to Ban Nicotine Pouches and Flavoured Nicotine Products
2FIRSTS.ai
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2025 Shenzhen 2FIRSTS Technology Co.,Ltd. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland. For Chinese mainland users, please visit https://cn.2firsts.com
English
English
中文